Silevertinib Shows 86% CNS Response Rate in Untreated Brain Metastases
BDTX sits 25% above its 52-week low of $1.6.
Summary
Black Diamond reported updated Phase 2 silevertinib data showing an 86% CNS objective response rate in patients with untreated brain metastases and a 15.0-month median progression-free survival. That is a strong efficacy readout for a micro-cap oncology name whose entire thesis rests on this program. The company had already scheduled a webcast for 7:30 a.m. ET today to present the data, and the 8-K with the same figures hit this morning. FDA feedback supports a clear path to potential registration in 1L EGFR-NCM NSCLC. Cash is the other half of the story: the last 10-Q cut runway guidance to Q2 2027 from H2 2028, so a positive data set raises the odds of a financing or partnership rather than removing the funding question.
At the time of this announcement, BDTX was trading at $2.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $106.9M. The 52-week trading range was $1.60 to $4.94. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.